Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD)

Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD)

The purpose of this study is to develop a pilot screening protocol, comparing cardiac point-of-care ultrasound (POCUS), electrocardiogram (EKG), serum biomarkers (N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin (hsTn)) with formal transthoracic echocardiogram (TTE) in pregnant women with methamphetamine use.

This is a pilot study that examines previously undiagnosed cardiac pathology utilizing transthoracic echocardiogram (TTE) in pregnant women with chronic methamphetamine use and assesses possible screening modalities (cardiac point-of-care ultrasound (POCUS), serum biomarkers, electrocardiogram (EKG)) in identifying underlying disease in this population. As this is a prospective observational study, we will assess pregnancy-related complications and care connections in the pilot tertiary academic setting.

Inclusion Criteria:

• 18 years or older > 20 weeks gestation admitted to the hospital
• Active patient-defined regular methamphetamine use for at least 1 year and any use within the last month
• Able to understand and provide informed consent
• Able to understand English

Exclusion Criteria:

These criteria will exclude women whose medications, personal traits, obstetric conditions, or diseases could confound cardiovascular risk.

• Prescribed stimulants
• Echocardiogram or EKG previously performed during current pregnancy
• Previous diagnosis of congestive heart dysfunction
• Previous diagnosis of pulmonary hypertension
• Previous myocardial infarction
• Previous diagnosis of endocarditis
• Prior cardiac intervention (repair of cardiac congenital lesion, valve replacement or repairs, percutaneous/operative treatment of arrhythmias)
• High-risk aortopathy (Marfan syndrome, bicuspid aortopathy, prior aortic dissection)